TARSUS PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
TARSUS PHARMACEUTICALS, INC. (TARS) reported Payments to Acquire Debt Securities, Available-for-sale of $129.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $2.40M, a 98.15% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $126.80M, a 0.98% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $35.58M, a 60.45% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $102.33M, a 385.34% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $393.19M, a 49.71% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $262.63M, a 816.23% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $28.66M, a 80.82% decline from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $149.44M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $129.20M 10-Q · filed 2026-08-06 | $164.78M derived: sum of 3 quarters · filed 2026-08-06 | $267.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $126.80M 10-Q · filed 2026-05-06 | $162.38M derived: sum of 2 quarters · filed 2026-05-06 | $264.71M derived: sum of 3 quarters · filed 2026-05-06 | $394.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $35.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $137.91M derived: sum of 2 quarters · filed 2026-02-23 | $267.62M derived: sum of 3 quarters · filed 2026-08-06 | $393.19M 10-K · filed 2026-02-23 |
| 2025-09-30 | $102.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $232.04M derived: sum of 2 quarters · filed 2026-08-06 | $357.61M 10-Q · filed 2025-11-04 | $447.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $129.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $255.27M 10-Q · filed 2026-08-06 | $345.24M derived: sum of 3 quarters · filed 2026-08-06 | $366.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $125.57M 10-Q · filed 2026-05-06 | $215.54M derived: sum of 2 quarters · filed 2026-05-06 | $236.62M derived: sum of 3 quarters · filed 2026-05-06 | $283.65M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $89.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $111.05M derived: sum of 2 quarters · filed 2026-02-23 | $158.08M derived: sum of 3 quarters · filed 2026-02-23 | $262.63M 10-K · filed 2026-02-23 |
| 2024-09-30 | $21.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $68.11M derived: sum of 2 quarters · filed 2025-11-04 | $172.66M 10-Q · filed 2025-11-04 | $172.66M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $47.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $151.58M 10-Q · filed 2025-08-06 | $151.58M derived: sum of 3 quarters · filed 2026-02-23 | $151.57M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $104.55M 10-Q · filed 2025-05-01 | $104.55M derived: sum of 2 quarters · filed 2026-02-23 | $104.55M derived: sum of 3 quarters · filed 2026-02-23 | $104.55M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$3.00K derived: sum of 2 quarters · filed 2026-02-23 | -$3.00K derived: sum of 3 quarters · filed 2026-02-23 | $28.66M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$3.00K derived: sum of 2 quarters · filed 2024-11-13 | $28.66M 10-Q · filed 2024-11-13 | $121.07M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $28.67M 10-Q · filed 2024-08-08 | $121.07M derived: sum of 3 quarters · filed 2025-02-25 | $178.10M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $28.67M 10-Q · filed 2024-05-08 | $121.07M derived: sum of 2 quarters · filed 2025-02-25 | $178.10M derived: sum of 3 quarters · filed 2025-02-25 | $178.10M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $92.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $149.44M derived: sum of 2 quarters · filed 2025-02-25 | $149.44M derived: sum of 3 quarters · filed 2025-02-25 | $149.44M 10-K · filed 2025-02-25 |
| 2022-09-30 | $57.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $57.03M derived: sum of 2 quarters · filed 2023-11-09 | $57.03M 10-Q · filed 2023-11-09 | $57.03M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 10-K · filed 2023-03-17 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |